Abstract
This case study documents the widening of therapeutic options in pediatric psoriasis, now comprising biologics as well. Until 2015, biological therapy of pediatric psoriasis with etanercept has been approved for children older than 4.
Another biologic became available to children now - adalimumab. Our case study describes an 11-year-old boy with severe psoriasis, which has been refractory to both local and systemic treatment (with methotrexate, cyclosporine, and retinoids).
Thus, treatment with adalimumab (0.8 mg/kg) was chosen. The boy's condition improved gradually, the PASI index decreasing from 26.8 to 5.5 during 3 months of therapy.
Adalimumab is well tolerated, without any systemic or local adverse effects.